Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Imlifidase - Hansa Biopharma

Next Previous
Drug Profile

Imlifidase - Hansa Biopharma

Alternative Names: EnzE programme - Hansa Biopharma AB; Enzyme-based antibody enhancement programme - Hansa Biopharma AB; HMed-IdeS; IDEFIRIX; Idefirix; IdeS; IgG-degrading enzyme of Streptococcus pyogenes; IgG-endopeptidase; Mac-1; Streptococcal cysteine proteinase

Latest Information Update: 28 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hansa Medical AB
  • Developer Asklepios BioPharmaceutical; Hansa Biopharma AB; Sarepta Therapeutics
  • Class Antibacterials; Antineoplastics; Antirheumatics; Bacterial proteins; Endopeptidases; Immunotherapies
  • Mechanism of Action Immunoglobulin G degraders; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Anti-glomerular basement membrane disease; Guillain-Barre syndrome; Transplant rejection
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Renal transplant rejection
  • Phase III Anti-glomerular basement membrane disease
  • Phase II Anti-neutrophil cytoplasmic antibody-associated vasculitis; Crigler-Najjar syndrome; Guillain-Barre syndrome; Thrombotic thrombocytopenic purpura
  • Preclinical Autoimmune disorders; Glycogen storage disease type II
  • No development reported Cancer; Duchenne muscular dystrophy; Limb girdle muscular dystrophies
  • Discontinued Rheumatoid arthritis; Streptococcal infections

Most Recent Events

  • 28 Aug 2026 No recent reports of development identified for phase-I development in Duchenne muscular dystrophy(In children) in Spain (IV, Infusion)
  • 18 Aug 2026 Launched for Renal transplant rejection (Prevention) in Australia (IV)
  • 01 Jul 2026 SERB Pharmaceuticals completes the acquisition of exclusive development and commercialisation rights to imlifidase in European Union, United Kingdom, Switzerland, Norway, Liechtenstein, Iceland and the Middle East and North Africa (MENA) region from Hansa Biopharma

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top